We are live on ! Find out more
TARS icon

Tarsus Pharmaceuticals
TARS

69 hedge funds and large institutions have $298M invested in Tarsus Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 26 increasing their positions, 18 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

28,900% more call options, than puts

Call options by funds: $870K | Put options by funds: $3K

44% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 18

0.13% more ownership

Funds ownership: 76.85% → 76.98% (+0.13%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

8% less funds holding

Funds holding: 75 → 69 (-6)

15% less capital invested

Capital invested by funds: $351M → $298M (-$52.7M)

27% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 15

Holders
69
Holders Change
-6
Holders Change %
-8%
% of All Funds
1.11%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
11
Increased
26
Reduced
18
Closed
15
Calls
$870K
Puts
$3K
Net Calls
+$867K
Net Calls Change
-$432K

Top Buyers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
+$8.69M
2
JFG
Jefferies Financial Group
New York
+$7.38M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$4.58M
4
BlackRock
BlackRock
New York
+$3.68M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$951K

Top Sellers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
-$8.94M
2
CAM
Cormorant Asset Management
Massachusetts
-$3.89M
3
TCM
TimesSquare Capital Management
New York
-$1.5M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$1.49M
5
TCM
Tang Capital Management
California
-$1.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
Legal & General Group
51
Legal & General Group
United Kingdom
$101K +$73.9K +4,463 +183%
UBS Group
52
UBS Group
Switzerland
$101K +$102K +6,158 +880%
Wells Fargo
53
Wells Fargo
California
$43.1K -$2.7K -163 -5%
Royal Bank of Canada
54
Royal Bank of Canada
Ontario, Canada
$43K +$41.5K +2,510 +567%
AB
55
Amalgamated Bank
New York
$34K – – –
AIP
56
Ameritas Investment Partners
Nebraska
$21.3K – – –
MLICM
57
Metropolitan Life Insurance Company (MetLife)
New York
$18.2K – – –
Citigroup
58
Citigroup
New York
$13.2K +$10.3K +620 +222%
TRCT
59
Tower Research Capital (TRC)
New York
$11K -$12.4K -748 -50%
Osaic Holdings
60
Osaic Holdings
Arizona
$8.57K +$6.11K +369 +185%
CUAMC
61
China Universal Asset Management Company
China
$3.97K +$4.48K +271 New
Dimensional Fund Advisors
62
Dimensional Fund Advisors
Texas
$2.93K +$951K +57,469 +40%
Fidelity Investments
63
Fidelity Investments
Massachusetts
$2.17K -$4.12K -249 -63%
Daiwa Securities Group
64
Daiwa Securities Group
Japan
$2K +$1.77K +107 New
US Bancorp
65
US Bancorp
Minnesota
$1.16K -$943 -57 -42%
IA
66
IFP Advisors
Florida
$1K +$496 +30 New
MPWT
67
MassMutual Private Wealth & Trust
Connecticut
$1K +$1.19K +72 +313%
S
68
SignatureFD
Georgia
$191 -$3.49K -211 -94%
TAM
69
Tucker Asset Management
Colorado
$58 – – –
CAC
70
Cowen and Company
New York
– -$8.94M -522,329 Closed
Jacobs Levy Equity Management
71
Jacobs Levy Equity Management
New Jersey
– -$1.49M -86,948 Closed
UOC
72
UBS O'Connor
Illinois
– -$1.04M -61,000 Closed
Two Sigma Investments
73
Two Sigma Investments
New York
– -$323K -18,851 Closed
XT
74
XTX Topco
Cayman Islands
– -$306K -17,865 Closed
MAM
75
Martingale Asset Management
Massachusetts
– -$246K -14,329 Closed
1 2
3
4

TARS Hedge Fund Activity: Q4 2022 in Review

69 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q4 2022, worth a combined $298M — down 15% from $351M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of TARS and 11 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 26 added.

The largest buyer was RTW Investments, adding an estimated $8.69M. The largest seller was Cowen and Company, exiting entirely with an estimated $8.94M sold.

  • 69 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q4 2022, down from 75 in Q3 2022.
  • Funds reported $298M of Tarsus Pharmaceuticals stock for Q4 2022, down 15% quarter-over-quarter.
  • 11 funds opened new Tarsus Pharmaceuticals positions in Q4 2022 and 15 closed out, a net change of -4 holders.
  • The largest Tarsus Pharmaceuticals buyer in Q4 2022 was RTW Investments, an estimated $8.69M added.
  • The largest Tarsus Pharmaceuticals seller in Q4 2022 was Cowen and Company, an estimated $8.94M sold.

Based on aggregated 13F filings for Q4 2022.